NCT02699749View on ClinicalTrials.gov

A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 24, 2016

Primary Completion Date

December 21, 2019

Study Completion Date

December 21, 2019

Conditions
Nonhematologic Neoplasms, Advanced
Interventions
DRUG

TAK-931

TAK-931 oral capsules.

Trial Locations (2)

Unknown

Kashiwa

Chuo-ku

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY